Disease · EFO_0009784
central serous retinopathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. central serous retinopathy. Diseases, record EFO_0009784. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009784
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- central serous retinopathy
- Open Targets ID
- EFO_0009784
- Other names
- central serous chorioretinopathy
- Highest stage of its drugs
- Phase 2/3, for 4 of its 19 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPLERENONE | CHEMBL1095097 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MALTODEXTRIN | CHEMBL2107951 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| MELATONIN | CHEMBL45 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FINASTERIDE | CHEMBL710 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BRINZOLAMIDE | CHEMBL220491 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETOCONAZOLE | CHEMBL157101 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIFEPRISTONE | CHEMBL1276308 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 4 | Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 2 | Mineralocorticoid receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 2 | https://conductscience.org/library/genes/760 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| IFNGR1 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3459 | Drugs and targets |
| IFNGR2 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3460 | Drugs and targets |
| MTNR1A | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/4543 | Drugs and targets |
| MTNR1B | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/4544 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor antagonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01990677 | Eplerenone for the Treatment of Central Serous Chorioretinopathy | Not applicable | 108 | 2017-06-29 | Central Serous Chorioretinopathy | EPLERENONE | Its record names the disease | ClinicalTrials.gov |
| NCT01325181 | Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy | Phase 1/2 | 34 | 2013-05-27 | Chronic Central Serous Chorioretinopathy | RANIBIZUMAB, VERTEPORFIN | Its record names the disease | ClinicalTrials.gov |
| NCT04356716 | Sildenafil for Treatment of Choroidal Ischemia | Phase 2 | 22 | 2025-07-04 | Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT01822561 | Eplerenone for Central Serous Chorioretinopathy | Phase 2 | 17 | 2018-05-16 | Central Serous Chorioretinopathy | EPLERENONE | Its record names the disease | ClinicalTrials.gov |
| NCT01710332 | The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy | Phase 2 | 12 | 2017-04-07 | Central Serous Chorioretinopathy | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01585441 | Finasteride for Chronic Central Serous Chorioretinopathy | Phase 2 | 6 | 2014-12-04 | Retinal Disease | FINASTERIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00837252 | Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy | Phase 1/2 | 5 | 2011-05-16 | Retinal Disease | FINASTERIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01468337 | Topical Interferon Gamma-1b for Central Serous Chorioretinopathy | Phase 1/2 | 5 | 2014-11-19 | Retinal Disease, Macular Disease | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT01227993 | Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy | Phase 1/2 | 3 | 2013-09-23 | Retinal Disease | FINASTERIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02081339 | Cohort Study of the Clinical Course of Macular Diseases in Japanese | 1,000 | Macular Disease | AFLIBERCEPT, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Low-fluence PDT vs Ranibizumab: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment | 16 of 18 | 2 of 16 | 34 | NCT01325181 | Trial comparisons |
| 25mg Eplerenone- Chronic CSCR Diagnosis vs Placebo- Chronic CSCR Diagnosis: deaths from any cause | 0 of 12 | 0 of 6 | 18 | NCT01990677 | Trial comparisons |
| 25mg Eplerenone- Chronic CSCR Diagnosis vs Placebo- Chronic CSCR Diagnosis: serious adverse events | 0 of 12 | 0 of 6 | 18 | NCT01990677 | Trial comparisons |
| Intravitreal Aflibercept Injection (x4) vs Intravitreal Aflibercept Injection (x6): serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT01710332 | Trial comparisons |
| Finasteride 5 mg vs Placebo: Number of Participants Who Withdrew From the Study | 0 of 3 | 0 of 3 | 6 | NCT01585441 | Trial comparisons |
| Finasteride 5 mg vs Placebo: Number of Participants With Adverse Reactions Related to the Investigational Product | 0 of 3 | 1 of 3 | 6 | NCT01585441 | Trial comparisons |
| Finasteride 5 mg vs Placebo: serious adverse events | 0 of 3 | 0 of 3 | 6 | NCT01585441 | Trial comparisons |
| Finasteride 5 mg vs Placebo: Number of Participants Presenting No Change in Size of Existing Plaque(s) on Indocyanine Green (ICG) Angiography at the Safety Visit Compared to Baseline | 3 of 3 | 2 of 2 | 5 | NCT01585441 | Trial comparisons |
| Finasteride 5 mg vs Placebo: Number of Participants Presenting No Change in Fluid Leakage at Month 3 Compared to Baseline | 2 of 2 | 2 of 3 | 5 | NCT01585441 | Trial comparisons |
| Finasteride 5 mg vs Placebo: Number of Participants Presenting No Change in Autofluorescence Patterns at Month 3 Compared to Baseline | 2 of 2 | 3 of 3 | 5 | NCT01585441 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009784
GET https://conductscience.org/api/diseases/v1/EFO_0009784/trials?page=2